May 23, 2024 | Press Releases
Phio to present a clinical study progress update on their lead clinical candidate, PH-762Marlborough, Massachusetts–(Newsfile Corp. – May 23, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
May 17, 2024 | Press Releases
–Fund invests in microcap equitiesMARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make...
May 16, 2024 | Press Releases
-Phio’s lead candidate, PH-762, targets PD-1, a critical target in cutaneous carcinomaMARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™...
May 15, 2024 | Press Releases
-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA...
May 9, 2024 | Press Releases
-Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 -Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
